LOS ANGELES, Nov. 1 /PRNewswire-FirstCall/ -- Sunnylife Global, Inc. announced today that it has signed an Exclusive License and Manufacturing Agreement with AOB Biotech, Inc. of Arcadia, CA. Under the initial 15 year term of the Agreement, Sunnylife Global will provide AOB Biotech with certain existing and future proprietary and intellectual property rights. AOB Biotech will market and distribute certain of the Company’s licensed products manufactured in accordance with the intellectual property rights.
“AOB will provide Sunnylife Global with an additional outlet for several of our anti-aging products, particularly in the Taiwan and Hong Kong markets where AOB is already well established,” said Richard Lo, President of Sunnylife Global, Inc. With its experience and resources in Asia and the US, including an FDA registered laboratory, AOB Biotech bridges western medical technology with eastern medicine methodology. AOB Biotech is in the process of establishing further sales channels in China, Japan, Southeast Asia, Europe, and the US.
About Sunnylife Global, Inc.
Sunnylife Global, Inc. has developed a Health Care Management System (HSMC) in conjunction with the Chinese Government Authorities that will result in delivering superior quality health care management to its members. The Company is in multiple joint-venture agreements with the government of China to renovate and revitalize China’s older hospital facilities in order to meet the current International standard. Sunnylife has developed the HCMS to meet that standard. In addition, the Company has patented natural, environmentally safe and economically affordable products which it sells to Chinese customers through seven different joint venture companies in China. Sunnylife represents an organization staffed with professional experts in product research, quality acceptance testing, and market development for service to China and the global markets.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. All forward-looking statements attributable to the Company, or persons acting for the Company, are expressly qualified in their entirety by these cautionary statements.
Contact: Investor Relations Fran Daniels, President Financial Sciences of America (310) 278-4413 finsci@earthlink.net
Sunnylife Global, Inc.
CONTACT: Investor Relations, Fran Daniels, President of Financial Sciencesof America, +1-310-278-4413, finsci@earthlink.net, for Sunnylife Global,Inc.
